New GLP-1 Pill, Orforglipron, Helps People Lose 23 Pounds in Study
WEDNESDAY, Aug. 27, 2025 — Eli Lilly says its new once-daily pill, orforglipron, helped people lose significant weight and lower blood sugar in a late-stage clinical trial.
The company plans to seek global regulatory approval later this year.
The study included people with overweight, obesity, and type 2 diabetes. Participants who took the highest dose of the drug (36 milligrams) lost an average of 22.9 pounds — about 10.5% of their body weight — after 72 weeks. The pill also lowered A1C levels — a measure of blood sugar control — by 1.8% on average, CNN reported.
Those results, which have not been peer-reviewed, were lower than weight loss figures announced earlier this month, when the company reported that the highest dose helped patients shed an average 27.3 pounds, or 12.4% of their body weight.
Unlike Rybelsus, the only semaglutide pill currently available, orforglipron doesn’t require strict fasting or limited water intake.
The pill offers an alternative to injections, which some people find difficult or unpleasant.
Eli Lilly says side effects were mostly mild to moderate, with upset stomach being the most common.
If approved, orforglipron could offer millions of people with obesity or type 2 diabetes another treatment option. The company is also testing whether the pill may help with other conditions, including high blood pressure and sleep apnea.
With earlier promising trial results, the company has been mass-producing the pills for months.
“That way, we’ll have adequate supply to meet demand,” Dr. Dan Skovronsky, Lilly’s chief scientific officer, told CNN.
Sources
- CNN, Aug. 26, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Weight-Loss Surgery Outperforms GLP-1 Drugs, Study Argues
FRIDAY, Sept. 19, 2025 — Cutting-edge drugs like Ozempic and Zepbound are all the rage for dropping excess pounds, but weight-loss surgery might have a better impact on...
Sepsis Risk Doubled With Type 2 Diabetes
FRIDAY, Sept. 19, 2025 — Type 2 diabetes appears to double a person’s risk for life-threatening sepsis, a new study says. Men and people under 60 with diabetes are...
Three Health Conditions Raise Death Risk For Fatty Liver Disease
FRIDAY, Sept. 19, 2025 — People with fatty liver disease are more likely to die early if they have one of three additional health problems, a new study says. High blood...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.